Author:
Citron Diane M.,Tyrrell Kerin L.,Merriam Vreni,Goldstein Ellie J. C.
Abstract
ABSTRACTNXL104, a novel β-lactamase inhibitor, was tested at a constant concentration of 4 μg/ml in combination with ceftazidime (CAZ), with and without added metronidazole, against 396 β-lactamase-producing strains of anaerobic bacteria. MIC50/MIC90values forBacteroides fragilisand theB. fragilisgroup were 8/16 and 64/>128 μg/ml, respectively. Although CAZ-NXL104 had limited activity against most anaerobic strains, in combination with metronidazole it shows potential for treating mixed infections involving resistantEnterobacteriaceaeand anaerobes.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Reviewing novel treatment options for carbapenem-resistant
Enterobacterales;Expert Review of Anti-infective Therapy;2024-01-10
2. Fifty years devoted to anaerobes: historical, lessons, and highlights;European Journal of Clinical Microbiology & Infectious Diseases;2023-11-16
3. What to Do with the New Antibiotics?;Antibiotics;2023-03-27
4. Antibacterial Agents;Principles and Practice of Pediatric Infectious Diseases;2023
5. New β-Lactam–β-Lactamase Inhibitor Combinations;Clinical Microbiology Reviews;2020-12-16